The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Drug interactions involving the new second- and third-generation antiepileptic drugs
Open accessAbstract
During the period 1989-2009, 14 new antiepileptic drugs (AEDs) were licensed for clinical use and these can be subdivided into new second- and third-generation AEDs. The second-generation AEDs comprise felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. The third-generation AEDs comprise eslicarbazepine acetate and lacosamide. The interaction propensity of AEDs is very important because all new AEDs are licensed, at least in the first instance, as adjunctive therapy. The present review summarizes the interactions (pharmacokinetic and pharmacodynamic) that have been reported with the newer AEDs. The pharmacokinetic interactions include those relating to protein-binding displacement from albumin in blood, and metabolic inhibitory and induction interactions occurring in the liver. Overall, the newer AEDs are less interacting because their pharmacokinetics are more favorable and many are minimally or not bound to blood albumin (e.g., eslicarbazepine, felbamate, gabapentin, lacosamide levetiracetam, rufinamide, topiramate and vigabatrin) and are primarily renally excreted or metabolized by noncytochrome P450 or uridine glucoronyl transferases (e.g., gabapentin, lacosamide levetiracetam, rufinamide, topiramate and vigabatrin) as opposed to hepatic metabolism which is particularly amenable to interference. Gabapentin, lacosamide, levetiracetam, pregabalin and vigabatrin are essentially not associated with clinically significant pharmacokinetic interactions. Of the new AEDs, lamotrigine and topiramate are the most interacting. Furthermore, the metabolism of lamotrigine is susceptible to both enzyme inhibition and enzyme induction. While the metabolism of felbamate, tiagabine, topiramate and zonisamide can be induced by enzyme-inducing AEDs, they are less vulnerable to inhibition by valproate. Noteworthy is the fact that only five new AEDs (eslicarbazepine, felbamate, oxcarbazepine, rufinamide and topiramate) interact with oral contraceptives and compromise contraception control. The most clinically significant pharmacodynamic interaction is that relating to the synergism of valproate and lamotrigine for complex partial seizures. Compared with the first-generation AEDs, the new second- and third-generation AEDs are less interacting, and this is a desirable development because it allows ease of prescribing by the physician and less complicated therapeutic outcomes and complications for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01561.x · Cited by 1,156
Self-citationClinically relevant drug interactions with antiepileptic drugs
Perucca, E. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02529.x · Cited by 602
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568
Pregabalin Pharmacology and Its Relevance to Clinical Practice
Ben‐Menachem, E. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.455003.x · Cited by 542
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Self-citationProgress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Self-citationPatsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00409-5 · Cited by 423
Self-citationPatsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00483-6 · Cited by 391
Self-citationLamotrigine substitution study: evidence for synergism with sodium valproate?
Brodie, M. J., & Yuen, A. W. C. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01007-8 · Cited by 379
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
Glauser, T., Kluger, G., Sachdeo, R., Krauss, G., Perdomo, C., & Arroyo, S. (2008) · Neurology · doi:10.1212/01.wnl.0000303813.95800.0d · Cited by 356
Perucca, E., Cloyd, J. C., Critchley, D. J. P., & Fuseau, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01665.x · Cited by 260
Elger, C., Halász, P., Maia, J., Almeida, L., Soares‐da‐Silva, P., & on behalf of the BIA‐2093‐301 Investigators Study Group (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01946.x · Cited by 252
Oral contraceptives reduce lamotrigine plasma levels
Sabers, A., Öhman, I., Christensen, J., & Tomson, T. (2003) · Neurology · doi:10.1212/01.wnl.0000076485.09353.7a · Cited by 250
Pisani, F., Oteri, G., Russo, M. F., Di Perri, R., Perucca, E., & Richens, A. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00832.x · Cited by 247
Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.09.005 · Cited by 225
Clinical Pharmacokinetics of Oxcarbazepine
May, T. W., Korn-Merker, E., & Rambeck, B. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342120-00002 · Cited by 224
Rosenfeld, W. E., Doose, D. R., Walker, S. A., & Nayak, R. K. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01123.x · Cited by 210
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions
Łuszczki, J. J. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70024-6 · Cited by 208
Eslicarbazepine Acetate (BIA 2-093)
Almeida, L., & Soares-da-Silva, P. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.10.005 · Cited by 185
Sidhu, J., Job, S., Singh, S., & Philipson, R. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02539.x · Cited by 185
Pharmacokinetic Interactions of Topiramate
Bialer, M., Doose, D. R., Murthy, B., Curtin, C., Wang, S.-S., Twyman, R. E., & Schwabe, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443120-00001 · Cited by 182
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(02)00106-7 · Cited by 172
Christensen, J., Petrenaite, V., Atterman, J., Sidenius, P., Öhman, I., Tomson, T., & Sabers, A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00997.x · Cited by 166
Ethinyl Estradiol, Not Progestogens, Reduces Lamotrigine Serum Concentrations
Reimers, A., Helde, G., & Brodtkorb, E. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.10105.x · Cited by 165
Induction of Ethinylestradiol and Levonorgestrel Metabolism by Oxcarbazepine in Healthy Women
Fattore, C., Cipolla, G., Gatti, G., Limido, G. L., Sturm, Y., Bernasconi, C., & Perucca, E. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00779.x · Cited by 165
Carbamazepine Toxicity with Lamotrigine: Pharmacokinetic or Pharmacodynamic Interaction?
Besag, F. M. C., Berry, D. J., Pool, F., Newbery, J. E., & Subel, B. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01356.x · Cited by 161
Doose, D. R., Wang, S., Padmanabhan, M., Schwabe, S., Jacobs, D., & Bialer, M. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.55602.x · Cited by 161
Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial
Glauser, T. A., Pellock, J. M., Bebin, E. M., Fountain, N. B., Ritter, F. J., Jensen, C. M., & Shields, W. D. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13101.x · Cited by 160
Sachdeo, R. C., Sachdeo, S. K., Walker, S. A., Kramer, L. D., Nayak, R. K., & Doose, D. R. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb00651.x · Cited by 151
Valproate-Ethosuximide Combination Therapy for Refractory Absence Seizures
Rowan, A. J., Meijer, J. W. A., de Beer-Pawlikowski, N. K. B., van der Geest, P., & Meinardi, H. (1983) · Archives of Neurology · doi:10.1001/archneur.1983.04050120047006 · Cited by 149
Langtry, H. D., Gillis, J. C., & Davis, R. (1997) · Drugs · doi:10.2165/00003495-199754050-00009 · Cited by 148
Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability
Gidal, B. E., Radulovic, L. L., Kruger, S., Rutecki, P. A., Pitterle, M. E., & Bockbrader, H. N. (2000) · Epilepsy Research · doi:10.1016/s0920-1211(00)00117-0 · Cited by 145
Brodie, M. J., Rosenfeld, W. E., Vázquez, B., Sachdeo, R., Perdomo, C. A., Mann, A., & Arroyo, S. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02160.x · Cited by 144
Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs
Spina, E., & Perucca, E. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2037.x · Cited by 143
Sargentini‐Maier, M. L., Rolan, P. E., Connell, J., Tytgat, D., Jacobs, T. G., Pigeolet, E., Riethuisen, J., & Stockis, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02829.x · Cited by 140
McLean, M. J. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb06001.x · Cited by 137
Efficacy and Safety of Lacosamide in Diabetic Neuropathic Pain
Wymer, J. P., Simpson, J. N., Sen, D. L., & Bongardt, S. (2009) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318196d2b6 · Cited by 136
New Antiepileptic Drugs: Review on Drug Interactions
Hachad, H., Ragueneau, I., & Levy, R. H. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200202000-00016 · Cited by 134
Initial Human Experience with Ganaxolone, a Neuroactive Steroid with Antiepileptic Activity
Monaghan, E. P., Navalta, L. A., Shum, L., Ashbrook, D. W., & Lee, D. A. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01486.x · Cited by 124
Bidirectional interaction of valproate and lamotrigine in healthy subjects*
Anderson, G. D., Yau, M. K. T., Gidal, B. E., Harris, S. J., Levy, R. H., Lai, A. A., Wolf, K. B., Wargin, W. A., & Dren, A. T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90130-7 · Cited by 123
Rolan, P. E., Sargentini‐Maier, M. L., Pigeolet, E., & Stockis, A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03158.x · Cited by 123
Adkins, J. C., & Noble, S. (1998) · Drugs · doi:10.2165/00003495-199855030-00013 · Cited by 121
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
Sargentini‐Maier, M. L., Espié, P., Coquette, A., & Stockis, A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017129 · Cited by 118
Palmer, K. J., & McTavish, D. (1993) · Drugs · doi:10.2165/00003495-199345060-00008 · Cited by 117
Clinical pharmacokinetics of new antiepileptic drugs
Walker, M. C., & Patsalos, P. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00021-6 · Cited by 114
Self-citationMcKee, P., Blacklaw, J., Forrest, G., et al. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04234.x · Cited by 114
Lackner, T. E., Cloyd, J. C., Thomas, L. W., & Leppik, I. E. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01294.x · Cited by 114
Lyseng-Williamson, K. A., & Yang, L. P. H. (2007) · Drugs · doi:10.2165/00003495-200767150-00008 · Cited by 114
The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder
Pollack, M. H., Roy‐Byrne, P., Ameringen, M. V., Snyder, H., Brown, C. E., Ondrasik, J., & Rickels, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1109 · Cited by 112
Antiepileptic drugs in epilepsy and other disorders—A population-based study of prescriptions
Landmark, C. J., Larsson, P. G., Rytter, E., & Johannessen, S. I. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.07.005 · Cited by 111
Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use
Herzog, A. G., Blum, A. S., Farina, E. L., Maestri, X. E., Newman, J. W. I., Garcia, E., Krishnamurthy, K. B., Hoch, D. B., Replansky, S., Fowler, K. M., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000344167.78102.f0 · Cited by 102
Trends in utilization of antiepileptic drugs in Denmark
Tsiropoulos, I., Gichangi, A., Andersen, M. T., Bjerrum, L., Gaist, D., & Hallas, J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00639.x · Cited by 101
May, T. W., Rambeck, B., & Jürgens, U. H. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199904000-00007 · Cited by 101
Chiron, C. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.10.001 · Cited by 100
Stiripentol kinetics in epilepsy: Nonlinearity and interactions
Levy, R. H., Loiseau, P., Guyot, M., Bléhaut, H., Tor, J., & Moreland, T. A. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.237 · Cited by 99
Lamotrigine toxicity secondary to sertraline
Kaufman, K. R., & Gerner, R. H. (1998) · Seizure · doi:10.1016/s1059-1311(98)80074-5 · Cited by 97
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive
Saano, V., Glue, P., Banfield, C. R., Reidenberg, P., Colucci, R. D., Meehan, J. W., Haring, P., Radwanski, E., Nomeir, A. A., Lin, C., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90172-8 · Cited by 93
Felbamate‐associated fatal acute hepatic necrosis
O’Neil, M. G., Perdun, C. S., Wilson, M., McGown, S. T., & Patel, S. (1996) · Neurology · doi:10.1212/wnl.46.5.1457 · Cited by 89
Ebert, U., Thong, N. Q., Oertel, R., et al. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000146 · Cited by 83
Tartara, A., Galimberti, C. A., Manni, R., MORINI, R., Limido, G., Gatti, G., Bartoli, A., STRADA, G., & Perucca, E. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00378.x · Cited by 79
Öhman, I., Luef, G., & Tomson, T. (2008) · Seizure · doi:10.1016/j.seizure.2007.11.017 · Cited by 79
Effect of Felbamate on Phenytoin and Carbamazepine Serum Concentrations
Graves, N. M., Holmes, G. B., Fuerst, R. H., & Leppik, H. E. (1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05458.x · Cited by 78
Levetiracetam Does Not Alter the Pharmacokinetics of an Oral Contraceptive in Healthy Women
Ragueneau, I., Levy, R. H., & Janik, F. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.57701.x · Cited by 76
Sachdeo, R. C., Sachdeo, S. K., Levy, R. H., Streeter, A. J., Bishop, F. E., Kunze, K. L., MATHER, G. G., Roskos, L. K., Shen, D. D., Thummel, K. E., et al. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.41701.x · Cited by 75
Effect of Felbamate on Plasma Levels of Carbamazepine and Its Metabolites
Albani, F., Theodore, W. H., Washington, P., Devinsky, O., Bromfield, E. B., Porter, R. J., & Nice, F. J. (1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb05624.x · Cited by 74
Porter, R. J., Nohria, V., & Rundfeldt, C. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.012 · Cited by 74
Disabling tremor after lamotrigine with sodium valproate
Reutens, D. C., Duncan, J. S., & Patsalos, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)91398-6 · Cited by 70
Self-citationDiscontinuation of Phenytoin and Carbamazepine in Patients Receiving Felbamate
Wagner, M., Graves, N. M., Marienau, K., Holmes, G. B., Remmel, R. P., & Leppik, I. E. (1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb04669.x · Cited by 70
Gender difference in management of epilepsy—what women are hearing
Crawford, P. M., & Lee, P. (1999) · Seizure · doi:10.1053/seiz.1999.0274 · Cited by 69
Evans, K. C., Simon, N. M., Dougherty, D. D., Hoge, E. A., Worthington, J. J., Chow, C., Kaufman, R. E., Gold, A. L., Fischman, A. J., Pollack, M. H., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.69 · Cited by 68
Antiepileptic drug utilization in children from 1997–2005—a study from the Netherlands
van de Vrie-Hoekstra, N. W., de Vries, T. W., van den Berg, P. B., Brouwer, O. F., & den Berg, L. T. W. D. J.-V. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0480-z · Cited by 67
Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction
Sisodiya, S. M., Sander, J. W. A. S., & Patsalos, P. N. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(01)00309-6 · Cited by 67
Self-citationOjemann, L. M., Shastri, R., Wilensky, A. J., Friel, P. N., Levy, R. H., McLean, J. R. N., & Buchanan, R. A. (1986) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198609000-00010 · Cited by 67
Pack, A. M., Davis, A. R., Kritzer, J., Yoon, A., & Camus, A. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2009.01.024 · Cited by 67
Drug Interactions Between Lamotrigine and Psychoactive Drugs
Reimers, A., Skogvoll, E., Sund, J. K., & Spigset, O. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000169418.31275.a7 · Cited by 66
Armijo, J. A., Bravo, J., Cuadrado, A., & Herranz, J. L. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199904000-00008 · Cited by 66
Pharmacological Management of Epilepsy: Recent Advances and Future Prospects
Landmark, C. J., & Johannessen, S. I. (2008) · Drugs · doi:10.2165/00003495-200868140-00001 · Cited by 63
Pharmacokinetics of Stiripentol in Normal Man: Evidence of Nonlinearity
Levy, R. H., Lin, H.-S., Bléhaut, H., & Tor, J. (1983) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1983.tb01799.x · Cited by 60
Effects of felbamate on the pharmacokinetics of phenobarbital
Reidenberg, P., Glue, P., Banfield, C. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90244-9 · Cited by 60
Bartoli, A., Gatti, G., Cipolla, G., Barzaghi, N., Véliz, G., Fattore, C., Mumford, J. P., & Perucca, E. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01240.x · Cited by 59
Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects
Hermann, R., Knebel, N. G., Niebch, G., Richards, L. S., Borlak, J., & Locher, M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0558-6 · Cited by 58
Eldon, M. A., Underwood, B. A., Randinitis, E. J., & Sedman, A. J. (1998) · Neurology · doi:10.1212/wnl.50.4.1146 · Cited by 58
The effect of felbamate on valproic acid disposition
Wagner, M., Graves, N. M., Leppik, I. E., et al. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.170 · Cited by 54
Griffith, S. G., & Dai, Y. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.019 · Cited by 53
Visual Field Severity Indices Demonstrate Dose‐Dependent Visual Loss from Vigabatrin Therapy
Conway, M. L., Cubbidge, R. P., & Hosking, S. L. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01249.x · Cited by 52
Ferron‐Brady, G., Patat, A. A., Parks, V., Rolan, P. E., & Troy, S. M. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01825.x · Cited by 47
Mula, M. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049311 · Cited by 47
Effect of Felbamate on Clobazam and Its Metabolite Kinetics in Patients With Epilepsy
Contin, M., Riva, R., Albani, F., & Baruzzi, A. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199912000-00004 · Cited by 46
Gabapentin can improve postural stability and quality of life in primary orthostatic tremor
Rodrigues, J. P., Edwards, D. J., Walters, S. E., Byrnes, M. L., Thickbroom, G. W., Stell, R., & Mastaglia, F. L. (2005) · Movement Disorders · doi:10.1002/mds.20392 · Cited by 45
Topiramate Serum Concentration-to-Dose Ratio
n, J. A., mez, M. C. G., Blanco, Y., Herranz, J. L., & Armijo, J. A. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200406000-00005 · Cited by 41
Italian Consensus Conference on Epilepsy and Pregnancy, Labor and Puerperium
Aguglia, U., Barboni, G., Battino, D., Cavazzuti, G. B., Citernesi, A., Corosu, R., Guzzetta, F. M., Iannetti, P., Mamoli, D., Patella, A., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01964.x · Cited by 40
Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children
Tran, A., Vauzelle-Kervroedan, F., Rey, E., Pons, G., d'Athis, P., Chiron, C., Dulac, O., Renard, F., & Olivé, G. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050147 · Cited by 30
Warfarin-Felbamate Interaction: First Report
Tisdel, K. A., Israel, D. S., & Kolb, K. W. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800620 · Cited by 16
Cited by
Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update
Patsalos, P. N., Spencer, E. P., & Berry, D. J. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000546 · Cited by 477
Self-citationAntiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Self-citationVeroniki, A. A., Cogo, E., Rios, P., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0845-1 · Cited by 339
Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs
Zaccara, G., & Perucca, E. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0714 · Cited by 305
Metadata
- Authors
- Johannessen Landmark, C., & Patsalos, P. N.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 10
- Issue
- 1
- Pages
- 119-140
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2132257746
- Cited by
- 321
- References
- 94
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.